EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Terazosin as a Non-Hormonal Treatment for Endometriosis

Ahmet Beyazıt iD, Okan Tutuk, Didar Gürsoy Kuzuluk

International Journal of Molecular Sciences · 02.05.2026 · 27 (9) · 4093

DOI: 10.3390/ijms27094093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.05.2026. Verfasst von Ahmet Beyazıt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Hatay Mustafa Kemal University, Antakya 31060, Hatay, Türkiye. Hauptthemen laut MEDLINE: Endometriosis, Prazosin. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Projects Coordination Unit of Hatay Mustafa Kemal University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometriosis is a chronic, estrogen-dependent inflammatory disease including aberrant local steroidogenesis, inflammation, angiogenesis, oxidative stress, and prostaglandin-mediated pain. Given the elevated adrenergic receptor expression in endometriotic lesions and the potential of terazosin to downregulate Steroidogenic Factor-1 (SF-1), this study aimed to evaluate terazosin as a non-hormonal therapy in a surgically induced rat endometriosis model. Forty female Wistar rats were randomized to sham, untreated endometriosis, leuprolide acetate or terazosin; two postoperative deaths yielded final group sizes of 10/9/10/9. Blinded histopathology verified successful lesion establishment. ELISA quantified SF-1, IL-6, IL-8, TNF-α, NF-κB, VEGF, HIF-1α, and PGE2 in lesion tissue, serum, and peritoneal lavage; oxidative status was assessed by TAS, TOS, and OSI. Compared with untreated endometriosis, terazosin significantly reduced SF-1, PGE2, IL-6, IL-8, TNF-α, VEGF and HIF-1α across compartments (all p < 0.001), comparable to leuprolide (p = 1.000). Terazosin also normalized oxidative stress by decreasing TOS/OSI and restoring TAS in tissue, serum, and peritoneal fluid (p < 0.001). NF-κB decreased in tissue and serum (p < 0.001) but not in peritoneal fluid (p = 0.206). Overall, terazosin produced leuprolide-like molecular benefits without hormonal suppression, supporting repurposing as a candidate non-hormonal therapy, while highlighting the need for longer-duration studies and randomized clinical trials given model and pain-assessment limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndometriosisPrazosinAnimalsFemaleRats, WistarRatsOxidative StressDisease Models, AnimalSteroidogenic Factor 1Cytokines

Stichwörter der Autor:innen

endometriosisinflammationrat modelsteroidogenic factor-1terazosin

Substanzen

TerazosinPrazosinSteroidogenic Factor 1Cytokines

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Hatay Mustafa Kemal University, Antakya 31060, Hatay, Türkiye.
  • Department of Physiology, Hatay Mustafa Kemal University, Antakya 31060, Hatay, Türkiye.
  • Department of Pathology, Hatay Mustafa Kemal University, Antakya 31060, Hatay, Türkiye.

ORCID-Profile: Ahmet Beyazıt

Förderung

  • Scientific Research Projects Coordination Unit of Hatay Mustafa Kemal University

Zitieren

APA

Beyazıt, A., Tutuk, O., & Kuzuluk, D. G. (2026). Terazosin as a Non-Hormonal Treatment for Endometriosis. International Journal of Molecular Sciences, 27(9), 4093. https://doi.org/10.3390/ijms27094093

Vancouver

Beyazıt A, Tutuk O, Kuzuluk DG. Terazosin as a Non-Hormonal Treatment for Endometriosis. International Journal of Molecular Sciences. 2026;27(9):4093. doi:10.3390/ijms27094093

BibTeX
@article{Beyazt2026,
  author = {Beyazıt, Ahmet and Tutuk, Okan and Kuzuluk, Didar Gürsoy},
  title = {Terazosin as a Non-Hormonal Treatment for Endometriosis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {4093},
  doi = {10.3390/ijms27094093}
}
Kostenlos starten →